logo-loader

BioLargo says subsidiary's Clyraguard protective spray inactivates SARS-CoV-2 virus in lab tests

Published: 12:37 19 May 2020 EDT

Clyraguard bottle
Clyraguard is colorless and odorless and has been found to be non-toxic, non-irritating, non-sensitizing and non-staining

BioLargo Inc (OTCQB:BLGO) announced Thursday that Clyraguard, a spray developed by subsidiary Clyra Medical Technologies, was shown to cause complete inactivation of the SARS-CoV-2 virus in lab testing.

Clyraguard is a personal protective spray designed to help frontline healthcare workers prevent cross-contamination of their personal protective equipment from SARS-CoV-2, the virus that causes COVID-19.

The product is colorless and odorless and has been found to be non-toxic, non-irritating, non-sensitizing and non-staining. Testing was conducted under the supervision of Dr Slobodan Paessler at the Galveston National Laboratory at the University of Texas Medical Branch.

READ: BioLargo Inc clocked record revenue in 2019 driven by new channel partnerships, commercial milestones

“We are very proud of the Clyra team for creating this powerful tool to help fight the spread of SARS-CoV-2,” BioLargo CEO Dennis Calvert said. “Clyraguard will help protect people as we continue to fight the spread of the pandemic and will help people get back to living their lives.”

Along with and in addition to its subsidiary Clyra Medical, BioLargo has developed several innovative and patented products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds (VOC) elimination and advanced wound care. 

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

19 minutes ago